AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04491032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal anesthesia
Description: Caudal epidural injection will be performed after induction of general anesthesia.
Study NCT00313950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine
Description: 0.5 mL, IM (MMR, Day 0); 0.5 mL, IM (HAV Day 28 and 168)
Study NCT00313950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella
Description: 0.5 mL, IM (HAV Day 0 and 168); 0.5 mL, IM (MMR, Day 0)
Study NCT00846261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use it to treatment bone nonunion (Ilzarov)
Description: Detect the variation of limb lengthening
Study NCT01317615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Participants started RAD001 treatment with a dose of 5 mg/day once daily. A dose decrease to 5 mg every other day was allowed if tolerability issues arose.
Study NCT01317615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was started at doses of 175 mg/m². Dose reductions of Paclitaxel to 135 mg/m2 was permitted if tolerability issues arose.
Study NCT01317615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was started at doses of Area under the Curve 5 (AUC 5). Dose reductions of carboplatin to AUC 4 was permitted if tolerability issues arose.
Study NCT01211964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 22811
Description: Oral administration of solution and tablet.
Study NCT01234610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Description: Patients will be asked to attend three exercise sessions per week for 12 weeks. They will exercise in groups of up to four per session and they will be supervised by an experienced exercise physiologist. Each session will comprise 5 to 10 min warm-up period (involving very light aerobic exercise and a range of gentle movements), 30 min of light-to-moderate intensity aerobic exercise (cycle-ergometry and or treadmill-walking), and a 5 to 10 min cool-down period involving low-intensity aerobic exercise and gentle stretching. The intensity of the aerobic exercise will be individualised and will be progressed gradually (if appropriate) during the course of the study.
Study NCT03430414 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcriptome Analysis
Description: Transcriptome Analysis of Formalin Fixed Paraffin Embedded biopsies
Study NCT02515838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevuparin
Description: The Drug Product sevuparin solution for IV infusion
Study NCT02515838 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for IV infusion
Study NCT02206763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib (MMB)
Description: Tablet(s) administered orally once or twice daily
Study NCT02206763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Tablet(s) administered orally once daily.
Study NCT03865758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IN2L computer system
Description: Therapists will use the IN2L computer system to choose videos, music, games and exercise specific to the rehabilitation needs and personal preferences of patients.
Study NCT03503084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classical Yang's TCC exercise
Study NCT03706261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MK-6240
Description: Administration of 5 mCi of 18F-MK-6240 for tau PET.
Study NCT03706261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Florbetaben
Description: Administration of 8.1 mCi as a slow single intravenous bolus (6 sec/mL) in a total volume of up to 10 mL of 18F-Florbetaben for Aβ PET imaging.
Study NCT03233919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comprehensive remote ischaemic conditioning
Description: comprehensive remote ischaemic conditioning will be induced using an automated RIC device: Per-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb. The first inflation began immediately following randomization after admission. In case 5 cycles of RIC were not fully completed when the first balloon inflation or thrombus aspiration was ready to be performed, PCI was not to be delayed.~Post-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb immediately after PPCI.~Delayed-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb once daily on 2-28 days after MI.
Study NCT04050098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release
Description: Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base).
Study NCT04050098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemigliptin tartrate sesquihydrate and metformin
Description: Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
Study NCT01487096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: film-coated tablet~oral administration
Study NCT01487096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (placebo for teriflunomide)
Description: film-coated tablet~oral administration
Study NCT03775772 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oral Health
Description: * test group will receive an dental hygiene program for one year~* control group will remain with dental hygiene regime like done before study participation (maximum of two dental hygiene Treatments per year)
Study NCT03775772 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bite Force
Description: * test group will receive physiotherapy with the aim of increasing muscle strength in chewing muscles for 3 months~* control group will remain without such training
Study NCT00005096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT01693055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltheraTM 100 shots
Description: UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
Study NCT00349752 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: certolizumab pegol 400 mg
Description: Certolizumab pegol 400 mg provided in solution for subcutaneous injection (2 x 200 mg/mL) in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
Study NCT00349752 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (commercially available sodium chloride 0.9% (preservative free)) provided for subcutaneous injection in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
Study NCT05041322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone
Description: Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.
Study NCT05041322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects take placebo pills (twice a day) for 14 Days.
Study NCT01434381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-EPA/Alhydrogel
Study NCT03589885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2 mL auto-injector
Description: All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
Study NCT03589885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1 mL prefilled syringe
Description: All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
Study NCT03589885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 2 mL auto-injector
Description: 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15 , 16 and 4-weekly thereafter until week 48
Study NCT03589885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab 1 mL prefilled syringe
Description: 2 x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
Study NCT03277144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TST-TriStaple(3lines stapler)Technology
Description: Duodenal stump closed using a Tristaple ( three-lines linear stapler) device
Study NCT02525796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplerenone
Description: eplerenone, titrated up to a maximum of 50mg BID
Study NCT02525796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amiloride
Description: amiloride, titrated up to a maximum of 10mg BID
Study NCT03277144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: other conventional techniques
Description: Duodenal stump closed using other conventional techniques entailing manual suture or mechanical devices with only two lines of sutures.
Study NCT02525796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02525796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinacalcet
Description: Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID
Study NCT02525796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID
Study NCT02525796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cinacalcet
Description: Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID
Study NCT03168321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-123 Lotion
Description: Tazarotene 0.045% Lotion
Study NCT03168321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-123 Vehicle Lotion
Description: Vehicle Lotion
Study NCT02992626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human-dog interaction
Description: The tests are completed in the presence of a dog. Further, before starting the tests, the children have 15 minutes to interact with the present dog.
Study NCT02992626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stuffed toy dog
Description: The tests are completed in the presence of a stuffed toy dog. Further, before starting the tests, the children have 15 minutes to play with the stuffed toy dog.
Study NCT02960438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: subcutaneous administration
Study NCT02960438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous administration
Study NCT03686150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 oral regimen
Description: Vitamin D3 oral regimens supplementation
Study NCT01723410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing about people
Description: Subjects will be asked to write about other people in their lives once a week for 6-weeks.
Study NCT01723410 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Writing about places, objects
Study NCT03565939 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trichuris suis ova
Description: Eggs from the pig whipworm
Study NCT03686150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 oral regimen
Description: Vitamin D3 oral regimens supplementation
Study NCT01072786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV Vaccine-Admixture 1
Description: One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 1 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3-3´D4Δ30, 10\^3 PFU of rDEN4Δ30)
Study NCT01072786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV Vaccine-Admixture 2
Description: One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 2 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3-3´D4Δ30, 10\^3 PFU of rDEN4Δ30-200,201)
Study NCT01072786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV Vaccine-Admixture 3
Description: One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 3 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, 10\^3 PFU of rDEN4Δ30)
Study NCT01072786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV Vaccine-Admixture 4
Description: One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 4 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, 10\^3 PFU of rDEN4Δ30-200,201)
Study NCT01072786 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One subcutaneous injection of a placebo containing vaccine diluent but no actual vaccine
Study NCT01072786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV Vaccine-Admixture 5
Description: One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 5 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
Study NCT00017394 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00017394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV
Study NCT00017394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01098994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin E
Description: Daily administration of 400 IU natural d-alpha tocopherol acetate for 8 weeks
Study NCT01098994 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dummy pills
Description: Daily placebo administration for 8 weeks
Study NCT03565939 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution without TSO
Study NCT01199783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Infusion (6 mg/kg/bodyweight) once daily
Study NCT01199783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: vancomycin once daily (effective blood-plasma concentration of 15 mg/L)
Study NCT02689999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrabeprazole 10 mg Enteric-Coated Tablets
Study NCT05927181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAOM
Description: In the TAOM group, the gap between the implant and the facial bone wall was grafted with inorganic bovine bone (Geistlich Bio-Oss®; Geistlich Pharma AG, Wolhusen, Switzerland) and, in addition, a connective tissue graft (CTG) was placed submucosally on the labial bone plate by means of an envelope technique.
Study NCT05927181 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAOM
Description: In the TAOM group, the gap between the implant and the facial bone wall was grafted with inorganic bovine bone (Geistlich Bio-Oss®; Geistlich Pharma AG, Wolhusen, Switzerland) and, in addition, a connective tissue graft (CTG) was placed submucosally on the labial bone plate by means of an envelope technique.
Study NCT02148913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 1: Carfilzomib 15 mg/m2
Description: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6
Study NCT02148913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 2: Carfilzomib 20 mg/m2
Description: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6
Study NCT02148913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 2b: Carfilzomib 20 mg/m2
Description: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 20 mg/m2 on day -2, -1 and + 5
Study NCT02148913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 3b: Carfilzomib 27 mg/m2
Description: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 27 mg/m2 on day -2, -1 and + 5
Study NCT01090375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT01090375 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non Exercise
Study NCT03648346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: HL217 Ophathalmic Solution BID
Description: Two drops of 3 mg/mL of the treatment in one eye twice a day
Study NCT03648346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: HL217 Ophathalmic Solution QID
Description: Two drops of 3 mg/mL of the treatment in one eye 4 times a day
Study NCT01912716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose indomethacin
Description: patients randomized to this intervention receive 200mg indomethacin
Study NCT01912716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard dose indomethacin
Description: patients randomized to this intervention receive 100mg indomethacin
Study NCT02152202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-upright position
Description: In this group patients' bed will be set into 45 degree angle during sleep in the night time.
Study NCT02152202 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supine position
Description: Control: Supine position during nocturnal sleep for at least two postoperative nights.
Study NCT02857829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CAF+
Description: CAF+ will be a blend consisting of caffeine (100 mg), L-theanine (200 mg), vinpocetine (40 mg), L-tyrosine (300 mg), pyridoxine (1 mg), and cobalamin (20 mg).
Study NCT02857829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine-alone
Description: Caffeine (100 mg)
Study NCT02857829 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice flour
Study NCT00733031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6918
Description: liquid suspension, daily, oral dose
Study NCT03648346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops
Study NCT03400254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Description: All patients will receive HCQ at a dose of 600 mg orally twice daily. This dose is the same in both phase Ib and phase II portions of the protocol. Capsules of HCQ are available in 200 mg strength, thus patients will initially start with 3 capsules twice daily for a total of 6 capsules per day. HCQ will be administered in divided doses (BID). When taking HCQ twice daily, the two daily doses should be taken 12 hours apart as close to 9am and 9pm as possible. Patients receiving antacids, sucralfate, cholestyramine, and/or bicarbonate should have the HCQ drug dose administered at least 1 hour before or 2 hours after these medications. Hydroxychloroquine will be obtained from the UPENN Investigational Drug Service (IDS).
Study NCT00733031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: intravenous, doses are on an intermittent schedule
Study NCT00733031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: intravenous, dose administered every 21-days